P1717: HEALTH-RELATED QUALITY OF LIFE AND TOLERABILITY OF LONCASTUXIMAB TESIRINE IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED IN A PHASE 2 CLINICAL TRIAL (LOTIS 2). (23rd June 2022) - Spira, A.; Liao, L.; Zhou, X.; Gnanasakthy, A.; Chen, L.; Ungar, D.; Yu, E.; Kilavuz, T.; Radford, J.; Hamadani, M.